Nasus Pharma Ltd. NSRX 深 沪
等待开盘 09-30 09:30:00 美东时间
7.55
-0.450
-5.62%
华盛通- 最 高7.99
- 今 开7.70
- 成交量 48.01万股
- 最 低 7.3796
- 昨 收 8.00
- 总市值 6840.00万
- 52周最高 9.9899
- 市盈率 静 --
- 换手率 5.30%
- 52周最低 7.23
- 委 比 0.00%
- 总股本 905.96万
- 历史最高 9.9899
- 量 比 29.25
- 振 幅 7.63%
- 历史最低 7.23
- 每 手 1
- 风险率 0.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22
Laidlaw & Co. analyst Yale Jen initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $22.
09-29 20:22
Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference
<p><p align="justify">Nasus Pharma Ltd., a clinical-stage pharmaceutical company developing innovative intranasal products for emergency medical conditions, announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025, from 7:00-7:30 a.m. ET. The virtual presentation will be led by Dan Teleman, Chief Executive Officer. The company focuses on intranasal powder products, such as its...
09-02 12:00
Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony
Nasus Pharma Ltd., a clinical-stage pharmaceutical company, announced it rang the Closing Bell at the New York Stock Exchange, marking a significant milestone in its effort to transform emergency medicine through needle-free, fast-acting intranasal therapies. The company, which specializes in developing proprietary intranasal powder products to address unmet medical needs such as severe allergic reactions and anaphylaxis, celebrated its recent li...
08-26 12:00
一周IPO观察：中慧生物/银诺医药大涨，双登股份招股，奥克斯过讯，Bullish美股上市，Gemini递表
港股IPO观察 截止2025年的第33周，港交所2家上市，1家招股，3家聆讯，8家递表。 当周上市（2家） 研发流感疫苗的生物医药公司 $中慧生物-B(02...
08-18 12:02
一周IPO丨引爆市场！银诺医药-B一度飙涨近300%，天岳先进预计下周三上市！
牛股频出！银诺医药-B首日涨超200%！创年内港股新股首日涨幅纪录；天岳先进超购倍数超2400倍！预计下周三上市；“币圈新贵”Bullish上市首日涨超80%>>
08-16 08:54
新股首日 | “第三极”交易所 MIAX IPO首日开盘大涨近30%，报29.68美元
“第三极”交易所 MIAX IPO首日开盘大涨近30%，报29.68美元，公司最新市值超23亿美元>>
08-15 01:03
Nasus Pharma Announces Closing of Initial Public Offering
<p>Nasus Pharma Ltd., a clinical-stage pharmaceutical company, has completed its initial public offering of 1.25 million ordinary shares at $8.00 per share, raising $10 million. The shares began trading on the NYSE American under the ticker "NSRX." The company plans to use the proceeds for its intranasal epinephrine program and general corporate purposes. Laidlaw & Company and Craft Capital Management acted as joint bookrunners. The offering was ...
08-14 20:05
Nasus Pharma Prices $10M Initial Public Offering Of 1.25M Ordinary Shares At $8.00 Per Share
The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional Phase 2 studies, and the
08-13 19:38
一周IPO丨中慧生物暗盘飙涨162%，中签一手赚超4000港元；“减肥药概念”银诺医药招股中
中慧生物暗盘飙涨162%，中签一手赚超4000港元；Firefly首日大涨34%，市值近85亿美元；“减肥药概念”银诺医药招股中；美国第四大期权交易所MIAX预计下周上市>>
08-09 12:32
